Pharmaceutical Services Offered in Hospitals

Size: px
Start display at page:

Download "Pharmaceutical Services Offered in Hospitals"

Transcription

1 Pharmaceutical Services Offered in Hospitals Product Services Research Services Teaching Services Support Services Clinical Services In-patients (hospitalized) Out-patients (ambulatory) In-patients (hospitalized) Out-patients (ambulatory)

2 Product Services To ensure the quality of the drugs used within the hospital It includes mainly: *Drug storage *Preparation for administration *Distribution to the patient care units

3 Product Services for Hospitalized Patients Medication Distribution Systems Intravenous Admixture System Floor Stock Distribution System Patient Prescription System Combined Stock-Patient Prescription System Unit Dose Distribution System TPN compounding Service Oncology Pharmacy Services Radiopharmacy Service Intravenous Additives Services

4 Medication Distribution Systems (MDS) Floor Stock Distribution System Patient Prescription System Combined Stock-Patient Prescription System Unit Dose Distribution System

5 Floor Stock Distribution System *This system delegates drug order interpretation, drug inventory, and drug preparation on the patient care units to the nurse. *The pharmacist sees only transcribed drug requisitions sent by nursing personnel. *The pharmacist dispenses multiple doses, bulk supplies of drugs which are not labeled for a specific patient

6 Advantages of Floor Stock Distribution System *Availability of required medications *Reduction of drug order transcriptions for the pharmacy *Reduction of number of personnel required Simplicity

7 Disadvantages of Floor Stock Distribution System wrong patient *High incidence of medication errors wrong drug wrong dose wrong route *No clinical role for the pharmacist wrong time Prescription monitoring Patient counseling Drug therapy monitoring *Limited capacity for proper storage facilities in each PCU *Increased danger of unnoticed drug deterioration *Greater chance for pilferage

8 Patient Prescription System *The nurse rather than the pharmacist continued to play the major role in drug preparation and drug order evaluation *The nurse transcribes this order onto a Medication Administration Profile & generates a drug order for pharmacy *The pharmacist dispenses a (2 5) day supply of medication which is labeled for a specific patient

9 Advantages of Patient Prescription System Over Floor Stock System *Reduce medication errors drugs are labeled MAP Limit the supply to prevent continuing treatment without review *Starting clinical role for the pharmacist Prescription monitoring *Facilitate patient billing

10 Disadvantages of Patient Prescription System *Limited clinical role for the pharmacist *Storage problems in patient care units *Applicable only in small hospitals

11 Combined Stock-Patient Prescription System In this system, medicines are supplied as floor stocks for those drugs in more or less frequent use and as prescription dispensed items for all others. The advantages and disadvantages of this combined system are similar to those of the complete floor stock and prescription order systems

12 Unit Dose Distribution System Unit dose is any physical quantity of a drug specified by a physician to be administered to a patient at one time, and not requiring any significant physical or chemical alterations before being administered

13 *The pharmacist has a more active role in the medication cycle *The pharmacist-physician interactive role began to emerge *The nurse returns to the patient care responsibilities The unit dose system is the most cost effective of all pharmacy distribution systems when the entire spectrum of drug delivery activities within a hospital is considered Unit Dose Distribution System

14 The advantages of unit dose systems over alternative distribution systems *A reduction in the incidence of medication errors. *A decrease in the total cost of medication related activities. *A more efficient usage of pharmacy and nursing personnel. *Improved overall drug control and drug use monitoring. *More accurate patient billings for drugs. *The elimination or minimization of drug credits. *Greater control by the pharmacist over pharmacy work load patterns and staff scheduling. *A reduction in the size of drug inventories located in PCU. *Greater adaptability to computerized and automated procedures.

15 Intravenous Admixture System A large percentage of all the drugs administered in hospitals are given in the form of intravenous injections

16 Intravenous Admixture System Intravenous lines peripheral central direct indirect

17 Intravenous Admixture System An intravenous admixture is the combination of two or more parenteral products in one container. Intravenous programs use two systems use of ready to administer premixed products available from manufacturers compounding special solutions for patients with specific medical requirements

18 Steps for intravenous admixture preparation (Parenteral Prescription) 1. Writing the admixture order 2. Checking the order 3. Clerical work (Full detailed Typed label & profile work sheet) 4. Preparation of admixture 5. Checking completed admixture 6. Delivery to patient area 7. Storage in patient area 8. Administration to patient

19 Aseptic preparation in hospitals TPN compounding Oncology pharmacy services Radiopharmacy Service Intravenous Additives

20 Total Parenteral Nutrition TPN Need for nutritional assessment on admission to the hospital

21 Nutritional Requirements macronutrients micronutrients carbohydrates proteins fats trace elements vitamins electrolytes

22 Routes of Nutrition Oral Enteral Parenteral Peripheral Central Direct Indirect

23 Peripheral Parenteral Nutrition (PPN) Given via a peripheral vein Limited duration ( 2 weeks) Central Parenteral Nutrition (CPN) Given via a central vein long term access Limited volume ( 4 liters daily) Larger volumes are possible Isotonicity and osmolarity should be adjusted Require good venous access Risk of phlebitis Greater flexibility of solution formulation Patient comfort No risk of phlebitis

24 Routes of Nutrition

25 Common TPN Complications Line complications such as sepsis (bacterial contamination), thrombosis and catheter malposition. Metabolic complications such as hyperglycemia, Hypoglycemia, fluid overload, electrolytes abnormality, acid-base imbalances, trace mineral deficiency Hepatic complications include liver dysfunction, painful hepatomegaly, and hyperammonemia.

26 Common TPN Complications Most of these complications can be avoided By: 1. Placing catheters by experienced physicians. 2. Consistently following strict protocols for aseptic line care. 3. Patient monitoring.

27 Nutrition Support Team *To reduce the morbidity & mortality from nutrition support *To ensure its application in a safe & effective manner

28 Nutrition Support Team Physician Pharmacist Nurse Dietitian Team manager -formula design -compatibilities -evaluation of interactions -solution compounding -metabolic monitoring -catheter care -patient education -metabolic monitoring Enteral nutrition Social worker Physical therapist

29 TPN Monitoring Parameters *Temperature *Weight *Nitrogen Balance *Plasma Proteins *Lab tests *Clinical status

30 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output Healthy adults excrete the same amount as is ingested (They are in N equilibrium) positive value negative value growth tissue repair pregnancy Burns & injuries fever fasting

31 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output 1. Determine nitrogen intake by dividing the daily protein intake by Determine nitrogen lost in urine by a 24 h urinary urea nitrogen test (UUN). 3. Add 4* to the UUN to account for non-urinary losses of nitrogen

32 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output Example: Protein intake: 90 gm, 24 hr UUN: 20 gm N intake = 90/6.25 = 14.4 gm N N total output = = 24 gm N N-balance = = -9.6 gm N This person is losing 9.6 X 6.25=62.5 gm protein per day protein intake should be increased by a factor = nitrogen balance X 6.25

33 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output Example: Protein intake: 95gm, 24 hr UUN: 15gm -24 g protein/day

34 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output Example: Protein intake: 100gm, 24 hr UUN: 12gm 0 g protein/day

35 TPN Monitoring Parameters *Nitrogen Balance = nitrogen input nitrogen output Example: Protein intake: 80gm, 24 hr UUN: 3gm +6 g protein/day

36 TPN Monitoring Parameters *Temperature *Weight *Nitrogen Balance *Plasma Proteins *Lab tests *Clinical status

37 *Lab tests Blood: TPN Monitoring Parameters daily for electrolytes (Na +, K +, Cl - ), Glucose and acid-base status. 3 times/week for BUN, Ca +,, P and plasma transaminases Twice/week for ammonia, Mg and plasma transaminases Weekly for Hgb, prothrombin time, Zn, Cu and triglycerides Urine: 4-6/day for glucose and ketones 2-4/day for specific gravity or osmolarity Weekly for urinary urea nitrogen

38 Intravenous Additives It is the administration of combined intravenous drugs

39 Intravenous Additives *Dilution, reconstitution & transfer to a device (e.g., syringe) for administration to the patient *Subcutaneous infusions of drug combinations used in palliative care *Prefilled syringes *Drugs addition to infusions on the ward, e.g: antibiotics, electrolytes, vitamins, heparin & aminophylline

40 Advantages of Intravenous Additives *Convenience and time saving *Reduction in the number of injections necessary *Treatment of several conditions simultaneously *Giving the drugs in controlled increments

41 Radiopharmacy Service Responsibilities of the pharmacist : *Procurement, storage and dispensing of radioisotopes used in clinical practice *Perform quantitative analysis and determine the isotopic purity of all radiopharmaceuticals dispensed *Formulate sterile and non-sterile radioactive dosage forms to meet the current needs of the medical staff *Prescribe and schedule doses, which is often complex

42 Oncology pharmacy services Cytotoxic drugs are therapeutic agents intended primarily for the treatment of cancer. They affect cell reproduction. They have been known to be non-selective. Many have proved to be carcinogens, mutagens or teratogens

43 Sources of Hazardous Drug Exposure (workplaces) Hospital settings Pharmacies (hospital and community) Analytical or research laboratories Doctor s surgeries Ambulatory clinics Patients and their homes Veterinary clinics Waste disposal facilities Ambulance vehicles

44 People at risk Nurses Medical officers Pharmacy staff Technicians Laboratory staff Research staff Ambulance officers Couriers & porters Pharmacy delivery personnel Veterinarians and veterinary nurses Cleaning and waste disposal staff Stores and warehouse workers Patients, family and friends

45 Symptoms reported amongst people dealing with cytotoxic drugs Contact dermatitis Liver damage Abdominal pain Abdominal pain Hair loss Nasal sores Vomiting Excretion of the drugs or metabolites in the urine local toxic or allergic reaction Foetal loss & malformations of the offspring. Alterations to normal blood cell counts

46 Safe Handling Methods The manipulation of cytotoxic drugs requires: -Critical aseptic technique -Signs and labels -Protective clothing -Certain work techniques -Emergency procedures for spillage management -Trained personnel During Preparation During administration During storage and distribution

47 Cytotoxic signs and labels Purple is the recognized colour denoting the presence of cytotoxic substance or waste

48 Cytotoxic signs and labels A purple label with labels should be used on: IV solution flasks Syringes spill kits pump cartridges laundry bags transport containers for drugs plastic bags sharps containers storage areas for cytotoxic substances containers of oral and topical materials containers used for storing &transporting waste

49 Protective clothes 6.Hooded coveralls or caps 1.Gown: Made of low permeability fabric with a solid front long sleeves Elastic or knit cuffs 5.Eye protection: Goggles or glasses with side shields transparent full face chemical splash shield 2.Surgical Gloves: Unpowdered Latex made long enough Of acceptable thickness & tactile sensation 4.Boots or overshoes: Impermeable High enough Sturdy soles Skid resistant 3.Respiratory protection:

PRESCRIBING INFORMATION. Dextrose Injection USP. (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher

PRESCRIBING INFORMATION. Dextrose Injection USP. (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher PRESCRIBING INFORMATION Dextrose Injection USP (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher Pfizer Canada Inc. 17300 Trans-Canada Highway Kirkland,

More information

Chapter 64 Administration of Injectable Medications

Chapter 64 Administration of Injectable Medications Chapter 64 Administration of Injectable Medications Injectable Medications Injection or intravenous (IV) infusion More invasive than administration by mouth, rectum, or through the skin Common methods

More information

Chapter 11. Preparing and Handling Sterile Products and Hazardous Drugs. Paradigm Publishing, Inc. 1

Chapter 11. Preparing and Handling Sterile Products and Hazardous Drugs. Paradigm Publishing, Inc. 1 Chapter 11 Preparing and Handling Sterile Products and Hazardous Drugs Paradigm Publishing, Inc. 1 Preparing Intravenous Products IV route of administration can be used to Reach therapeutic drug serum

More information

10/28/2015. Disclaimer. Disclaimer

10/28/2015. Disclaimer. Disclaimer Disclaimer Omnicare, Inc., as a provider of Infusion Pharmacy Services, is committed to the establishment and maintenance of the highest quality of care in infusion therapy services. This Infusion Therapy

More information

ASEPTIC DISPENSING TECHNIQUES/DRUG- NUTRIENT INTERACTIONS

ASEPTIC DISPENSING TECHNIQUES/DRUG- NUTRIENT INTERACTIONS ASEPTIC DISPENSING TECHNIQUES/DRUG- NUTRIENT INTERACTIONS HARBANS KAUR DHILLON PRESIDENT OF PENSMA KUALA LUMPUR MALAYSIA PENSA 2007 University Malaya Medical Centre Kuala Lumpur ASEPTIC DISPENSING Ppn

More information

Hazardous Drug Safety

Hazardous Drug Safety Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions: To receive credit for completion: 1. Read the content

More information

ZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection

ZANOSAR 1g. STREPTOZOCINE Lyophilised powder for solution for injection PACKAGE LEAFLET: INFORMATION FOR THE USER ZANOSAR 1g STREPTOZOCINE Lyophilised powder for solution for injection Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

STANDARD OPERATING PROCEDURES (SOP) FOR CARCINOGENS

STANDARD OPERATING PROCEDURES (SOP) FOR CARCINOGENS STANDARD OPERATING PROCEDURES (SOP) FOR CARCINOGENS INTRODUCTION: Standard operating procedures (SOP) are intended to provide you with general guidance on how to safely work with a specific class of chemical

More information

British Columbia Cancer Agency

British Columbia Cancer Agency Page 1 of 12 A. SCOPE This Policy covers the preparation, administration, and disposal of hazardous drugs. See Cancer Drug Manual Appendix 5 for the Hazardous Drug List. (www.bccancer.bc.ca/hpi/drugdatabase/appendices)

More information

Policy for the safe handling and administration of cytotoxic drugs for Children, Teenagers and Young Adults with Cancer

Policy for the safe handling and administration of cytotoxic drugs for Children, Teenagers and Young Adults with Cancer Policy for the safe handling and administration of cytotoxic drugs for Children, Teenagers and Young Adults with Cancer Introduction Cytotoxic drugs are used to treat cancer and a number of other disorders.

More information

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that

More information

METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF

METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Mary Pack Arthritis Program METHOTREXATE CLINICAL PRACTICE GUIDELINES FOR STAFF Handling of premixed injectable Methotrexate (MTX) by employees who are pregnant, breast-feeding or attempting to reproduce

More information

IV Fluids Nursing B23 Objectives Serum Osmolality 275 to 295 Isotonic

IV Fluids Nursing B23 Objectives Serum Osmolality 275 to 295 Isotonic 1 IV Fluids Nursing B23 2 Objectives 3 Serum Osmolality Serum osmolality solute concentration of a solution Higher osmolality means greater pulling power for water Normal serum osmolality is 275 to 295

More information

SARASOTA MEMORIAL HOSPITAL

SARASOTA MEMORIAL HOSPITAL SARASOTA MEMORIAL HOSPITAL NURSING PROCEDURE TITLE: ISSUED FOR: PARENTERAL NUTRITION AND INTRAVENOUS FAT EMULSION (ADULT AND PEDIATRICS) Nursing DATE: REVIEWED: PAGES: RESPONSIBILITY: RN, LPN II 12/80

More information

Network Guidance for Handling the Spillage of Cytotoxic and Anti-Cancer Drug

Network Guidance for Handling the Spillage of Cytotoxic and Anti-Cancer Drug Network Guidance for Handling the Spillage of Cytotoxic and Anti-Cancer Drug West Midlands Expert Advisory Group for Systemic Anti-Cancer Therapy (SACT) Page 1 of 8 West Midlands Clinical Networks and

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

IV Fluids. Nursing B23. Objectives. Serum Osmolality

IV Fluids. Nursing B23. Objectives. Serum Osmolality IV Fluids Nursing B23 Objectives Discuss the purpose of IV Discuss nursing interventions in IV therapy Identify complications of IV therapy Differentiate between peripheral line, central line, and PICC

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Risk Management in Parenteral Nutrition. J. Boullata

Risk Management in Parenteral Nutrition. J. Boullata Risk Management in Parenteral Nutrition J. Boullata Objectives Upon completion of this session, the participant will be able to: Describe safety issues with parenteral nutrition (PN) Present the PN-use

More information

247 CMR BOARD OF REGISTRATION IN PHARMACY

247 CMR BOARD OF REGISTRATION IN PHARMACY 247 CMR 18.00: NON-STERILE COMPOUNDING Section 18.01: Authority and Purpose 18.02: Non-Sterile Compounding Process 18.03: Non-Sterile Compounding Facility 18.04: Non-Sterile Compounding Equipment 18.05:

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion

Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion Package leaflet: Information for the user Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion Read all of this leaflet carefully before you start using

More information

Peptide Receptor Radionuclide Therapy (PRRT) Lu-177

Peptide Receptor Radionuclide Therapy (PRRT) Lu-177 PATIENT EDUCATION patienteducation.osumc.edu Peptide Receptor Radionuclide Therapy (PRRT) Lu-177 What is a neuroendocrine tumor? Neuroendocrine cells are mainly found in your bowel, pancreas and lungs.

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Pharmaceutical risk management strategies for parenteral nutrition. J. Eastwood (UK)

Pharmaceutical risk management strategies for parenteral nutrition. J. Eastwood (UK) ESPEN Congress Leipzig 2013 Pharmaceutical Session Pharmaceutical risk management strategies for parenteral nutrition J. Eastwood (UK) Pharmaceutical risk management strategies for parenteral nutrition

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion

SUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Synthamin 14, 8.5% Amino Acid Intravenous Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION L-Leucine Ph. Eur 0.620% w/v L-Isoleucine

More information

E.N : Tubal Feeding Systems ; Closed vs. Open

E.N : Tubal Feeding Systems ; Closed vs. Open E.N : Tubal Feeding Systems ; Closed vs. Open Dr:Enas Mogawer, MD Head Of Clinical Nutrition Department,AFSH Professor Of Internal Medicine Kasr El Aini Medical Consultant Of Clinical Nutrition And Obesity

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug.

DISPENSING OR SELLING NALOXONE. Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: April 21, 2017 Purpose The intent of this document is to provide

More information

Nutrition Support in Children. Lyon 21 sept 2013

Nutrition Support in Children. Lyon 21 sept 2013 Nutrition Support in Children Lyon 21 sept 2013 Malnutrition : why detecting it in children? Alters cognitive development (observational or interventional studies) Responsible for prolongation of hospitalisation

More information

Nutrition care plan for surgical patients. Objectives

Nutrition care plan for surgical patients. Objectives Slide 1 Nutrition care plan for surgical patients Surgical Nutrition Training Module Level 1 Philippine Society of General Surgeons Committee on Surgical Training In this session we will discuss the most

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET 1. PRODUCT NAME ADDAVEN (infusion, solution concentrate) NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 ml ampoule of Addaven contains: Chromic chloride hexahydrate 53.33 µg

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Material Safety Data Sheet CISPLATIN INJECTION SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS

Material Safety Data Sheet CISPLATIN INJECTION SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS Material Safety Data Sheet CISPLATIN INJECTION SECTION 1 - PRODUCT MSDS NAME: Cisplatin Injection, BP SYNONYMS: Cis-Diamminedi-chloroplatinum (II) SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS Active:

More information

Neonatal Parenteral Nutrition Guideline Dr M Hogan, Maire Cullen ANNP, Una Toland Ward Manager, Sandra Kilpatrick Neonatal Pharmacist

Neonatal Parenteral Nutrition Guideline Dr M Hogan, Maire Cullen ANNP, Una Toland Ward Manager, Sandra Kilpatrick Neonatal Pharmacist CLINICAL GUIDELINES ID TAG Title: Author: Designation: Speciality / Division: Directorate: Neonatal Parenteral Nutrition Guideline Dr M Hogan, Maire Cullen ANNP, Una Toland Ward Manager, Sandra Kilpatrick

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS

APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS SmPC Country: Lebanon Date of approval : 17/08/2011 Procedure : National APPENDIX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1- NAME OF THE MEDICINAL PRODUCT DECAN, concentrate for solution for infusion 2- QUALITATIVE

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Animal Health Pfizer Inc 235 East 42nd Street New York, NY 10017 Poison Control Center Phone: 1-866-531-8896

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 October 2011 PEDIAVEN AP-HP G15, solution for infusion 1000 ml of solution in two chamber bag, B/4 (CIP code: 419

More information

ISMP guidelines that support intravenous drug delivery system safety

ISMP guidelines that support intravenous drug delivery system safety ISMP guidelines that support intravenous drug delivery system safety Michael R. Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP Institute for Safe Medication Practices Sterile Compounding Errors and Patient

More information

TOTAL PARENTERAL NUTRITION

TOTAL PARENTERAL NUTRITION TOTAL PARENTERAL NUTRITION Indication See algorithm. Timing Start TPN as indicated on algorithm 1. There is no need to build up TPN volume. The volume of TPN (including lipids) should equate to the total

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Aqupharm 3 Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients Sodium Chloride Glucose Anhydrous

More information

MATERIAL SAFETY DATA SHEET (MSDS)

MATERIAL SAFETY DATA SHEET (MSDS) MATERIAL SAFETY DATA SHEET (MSDS) SECTION I - MATERIAL IDENTIFICATION AND USE Material Name: Manufacturer s Name: Address: Supplier s Name: Address: Chemical Name: Chemical Family: Chemical Formula: Trade

More information

Helping to protect you from exposure to hazardous drugs

Helping to protect you from exposure to hazardous drugs Helping to protect you from exposure to hazardous drugs Closed system solution: Texium closed male luer and SmartSite needle-free valve products What you can t see can hurt you The risks are well documented

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET 300 Northfield Road Bedford, OH 44146 Telephone: (440) 232-3320 -or- (800) 562-4797 MATERIAL SAFETY DATA SHEET Section I - IDENTITY Common/Trade Name: Sterile Cytarabine, USP (100mg, 500mg, 1g or 2g/vial

More information

About the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p.

About the PCTB Examination Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. Preface p. ix About the PCTB Examination p. xii Assisting the Pharmacist in Serving Patients p. 1 Filling the Medication Order p. 3 Receiving the Medication Order p. 4 The Retail Medication Order p. 6

More information

P 1 Summary P 2 3 Part 1 General Information P 4 7 Part 2 Exposure among healthcare workers P 8 11 Part 3 Health Effects

P 1 Summary P 2 3 Part 1 General Information P 4 7 Part 2 Exposure among healthcare workers P 8 11 Part 3 Health Effects TOXICOLOGY PROFILE METHOTREXATE IN THE HEALTH CARE INDUSTRY P1Summary P23Part1GeneralInformation P47Part2Exposureamonghealthcareworkers P811Part3HealthEffects P8PulmonaryEffects P8EffectsonBone P8Hepatotoxicity

More information

Version: 3.0 Head of Chemotherapy (HoC)/ Lead cancer clinician (LCC) / Lead cancer nurse (LCN) Reviewed by Chemo Working Group April 2016

Version: 3.0 Head of Chemotherapy (HoC)/ Lead cancer clinician (LCC) / Lead cancer nurse (LCN) Reviewed by Chemo Working Group April 2016 Policy for the use of personal protective equipment when handling chemotherapy, v 3.0 POLICY FOR THE USE OF PERSONAL PROTECTIVE EQUIPMENT WHEN HANDLING CHEMOTHERAPY, SPILLAGE OF CHEMOTHERAPY, BODY WASTE

More information

PARENTERAL NUTRITION

PARENTERAL NUTRITION PARENTERAL NUTRITION DEFINITION Parenteral nutrition [(PN) or total parenteral nutrition (TPN)] is the intravenous infusion of some or all nutrients for tissue maintenance, metabolic requirements and growth

More information

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved Chapter 11 PREVENTING INFECTION Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from infection.

More information

UNIT I EVOLUTION OF THE PHARMACY

UNIT I EVOLUTION OF THE PHARMACY Contents UNIT I EVOLUTION OF THE PHARMACY........................ 1 Chapter 1 Pharmacy History................................................. 3 Egyptian History 4 Greek Influence 4 British Apothecaries

More information

1. IDENTIFICATION OF SUBSTANCE PODOPHYLLUM RESIN 25-50% IN BENZOIN Name: TINCTURE

1. IDENTIFICATION OF SUBSTANCE PODOPHYLLUM RESIN 25-50% IN BENZOIN Name: TINCTURE According to ISO 11014-1 Page 1 of 5 1. IDENTIFICATION OF SUBSTANCE PODOPHYLLUM RESIN 25-50% IN BENZOIN Name: TINCTURE Manufacturer: Information Department: Department of Pharmacy Duke University Medical

More information

PRODUCT: Ethyl alcohol (denatured) CHEMICAL ABSTRACT NO.: Mixture. Ethyl alcohol ppm Flammable

PRODUCT: Ethyl alcohol (denatured) CHEMICAL ABSTRACT NO.: Mixture. Ethyl alcohol ppm Flammable MATERIAL SAFETY DATA SHEET ETHYL ALCOHOL (DENATURED) Section I - IDENTIFICATION PRODUCT: Ethyl alcohol (denatured) SYNONYMS: Denatured ethanol CHEMICAL FORMULA: C 2 H 5 OH CHEMICAL ABSTRACT NO.: Mixture

More information

REFERENCES American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:

REFERENCES American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63: Ordering and Handling Applies To: UNM Hospitals Responsible Department: Pharmacy Revised: 8/2017 Procedure Patient Age Group: ( ) N/A (X) All Ages ( )Newborns ( )Pediatric ( )Adult DESCRIPTION/OVERVIEW

More information

Material Safety Data Sheet

Material Safety Data Sheet Material Safety Data Sheet NFPA HMIS Personal Protective Equipment 2 Health Hazard Fire Hazard 2 See Section 15. Section 1. Chemical Product and Company Identification Common Name/ Trade Name Manufacturer

More information

Material Safety Data Sheet

Material Safety Data Sheet Material Safety Data Sheet Kit for the Preparation of Technetium Tc 99m Pyrophosphate Injection For Diagnostic Use ISSUE DATE: 20-Jun-08 ORIGINATOR: P.E. Buck REVIEWER: Lars Waldmann CHEMICAL PRODUCT/COMPANY

More information

STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS

STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS STANDARD OPERATING PROCEDURE #714 USE OF MPTP IN NHPS 1. PURPOSE This Standard Operating Procedure (SOP) describes the guidelines for the use of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in

More information

Guideline scope Neonatal parenteral nutrition

Guideline scope Neonatal parenteral nutrition NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Neonatal parenteral nutrition The Department of Health in England has asked NICE to develop a new guideline on parenteral nutrition in

More information

Parenteral and Enteral Nutrition

Parenteral and Enteral Nutrition Parenteral and Enteral Nutrition Audis Bethea, Pharm.D. Assistant Professor Therapeutics I December 5 & 9, 2003 Parenteral Nutrition Definition process of supplying nutrients via the intravenous route

More information

USP 800 and Hazardous Medications

USP 800 and Hazardous Medications USP 800 and Hazardous Medications Trung H. Nguyen, PharmD and Alesha Davis, CPhT Dayton VA Medical Center Trung.Nguyen610@va.gov Alesha.Davis@va.gov The speaker has no actual or potential conflict of interest

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MATERIAL SAFETY DATA SHEET SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY Pfizer Inc Pfizer Animal Health 235 East 42nd Street New York, NY 10017 Product name Therapeutic use Description Emergency telephone

More information

Material Safety Data Sheet. Mitomycin for Injection

Material Safety Data Sheet. Mitomycin for Injection Material Safety Data Sheet Mitomycin for Injection SECTION 1 - PRODUCT MSDS ME: Mitomycin for Injection SYNONYMS: mitomycin-c SECTION 2 COMPOSITION, INFORMATION ON INGREDIENTS ACTIVE: Mitomycin ICTIVE:

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Intravenous Fluid and Drug Therapy

Intravenous Fluid and Drug Therapy 11 Intravenous Fluid and Drug Therapy OUTLINE Overview Direct Intravenous Injections Continuous Intravenous Injections Solution Additives Calculating IV Components as Percentages Calculating IV Flow Rates

More information

Model Standards for Pharmacy Compounding of Non-Sterile Preparations

Model Standards for Pharmacy Compounding of Non-Sterile Preparations Model Standards for Pharmacy Compounding of Non-Sterile Preparations Published with the Guidance Document For Pharmacy Compounding of Non-Sterile Preparations National Association of Pharmacy Regulatory

More information

Personal Protective Equipment:

Personal Protective Equipment: have, at a minimum a legible label to identify the contents even if it is water or benign material. Hazardous chemical containers must have the following: - Original manufacturer label with the date received

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 Emergency telephone number:

More information

Material Safety Data Sheet According to REACH regulation 1907/2006 Annex II

Material Safety Data Sheet According to REACH regulation 1907/2006 Annex II 1. Identification of the substance 1.1 Identification of the substance or preparation Name: Micro-Blaze Out Plus AFFF 1.2 Use of the substance/preparation Main use category : Industrial 1.3 Company/undertaking

More information

1. IDENTIFICATION OF SUBSTANCE OXYMETAZOLINE & TETRACAINE TOPICAL Name: SOLUTION

1. IDENTIFICATION OF SUBSTANCE OXYMETAZOLINE & TETRACAINE TOPICAL Name: SOLUTION Page 1 of 5 1. IDENTIFICATION OF SUBSTANCE OXYMETAZOLINE & TETRACAINE TOPICAL Name: SOLUTION Manufacturer: Information Department: Department of Pharmacy Duke University Medical Center Box 3089 Durham,

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Greenstone Limited 100 Route 206 North Peapack, NJ 07977 Emergency telephone number: 800-435-7095 Pfizer Ltd Ramsgate

More information

Material Safety Data Sheet According to ISO Page 1 of 6

Material Safety Data Sheet According to ISO Page 1 of 6 According to ISO 11014-1 Page 1 of 6 1. IDENTIFICATION OF SUBSTANCE Name: Manufacturer: Information Department: SMOG ENEMAS Department of Pharmacy Duke University Medical Center Box 3089 Durham, NC 27710

More information

This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries.

This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries. This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries. SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product

More information

DuPont StoneTech Professional POLISHING POWDER 900

DuPont StoneTech Professional POLISHING POWDER 900 This SDS adheres to the standards and regulatory requirements of the United States and may not meet the regulatory requirements in other countries. SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product

More information

Phosphoremia (mmol/l) Calcemia (mmol/l) Postnatal age (days) Postnatal age (days) Urinary Calcium (mg/kg/d) Phosphoremia (mmol/l)

Phosphoremia (mmol/l) Calcemia (mmol/l) Postnatal age (days) Postnatal age (days) Urinary Calcium (mg/kg/d) Phosphoremia (mmol/l) 3,0 3,2 Calcemia (mmol/l) 2,8 2,6 2,4 2,2 2,0 1,8 Phosphoremia (mmol/l) 3,0 2,8 2,6 2,4 2,2 2,0 1,8 1,6 1,4 1,2 1,6 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Postnatal age (days) 1,0 0 1 2 3 4 5 6 7 8 9 10 11

More information

Patient Preparation Unique patient preparation requirements are listed under each test in the Test Directory.

Patient Preparation Unique patient preparation requirements are listed under each test in the Test Directory. Specimen Collection Lab results are only as good as the specimen provided. Patient preparation, venipuncture technique, specimen handling, and transportation can all affect the quantity of results. Health

More information

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. TITLE PARENTERAL NUTRITION ADMINISTRATION AND MONITORING SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Pharmacy Services, Nutrition Services, and Health

More information

Chapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.

Chapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved. Chapter 12 Preventing Infection Infection Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from

More information

Nutrition Therapy. Medical Coverage Policy Enteral/Parenteral EFFECTIVE DATE: POLICY LAST UPDATED: 11/20/2018 OVERVIEW

Nutrition Therapy. Medical Coverage Policy Enteral/Parenteral EFFECTIVE DATE: POLICY LAST UPDATED: 11/20/2018 OVERVIEW Medical Coverage Policy Enteral/Parenteral Nutrition Therapy EFFECTIVE DATE: 01 20 2007 POLICY LAST UPDATED: 11/20/2018 OVERVIEW This policy describes the reimbursement for enteral and parenteral nutrition

More information

Nutritional intervention in hospitalised paediatric patients. Dr Y.K.Amdekar

Nutritional intervention in hospitalised paediatric patients. Dr Y.K.Amdekar Nutritional intervention in hospitalised paediatric patients Dr Y.K.Amdekar Back to basics Suboptimal nutrient intake is always dangerous in health and more so in disease to feed or not to feed is it a

More information

Aseptic Technique and Sterile Compounding

Aseptic Technique and Sterile Compounding Aseptic Technique and Sterile Compounding Chapter 12 1 Introduction Hospital technician crucial responsibility: Proper preparation of parenteral products Contamination must be reduced when preparing parenterals

More information

SECTION 1 - IDENTIFICATION

SECTION 1 - IDENTIFICATION 1 of 5 11/25/2009 9:53 AM TARKSOL GREEN Tarksol Aqua Kleen C Material Safety Data Sheet Trade Name: Tarksol Aqua Kleen C Manufacturer: Tarksol, Inc. 3400 Ridge Road West, S-300 Rochester, New York 14626

More information

Kovanaze TM Nasal Spray (6 mg Tetracaine Hydrochloride and 0.1 mg Oxymetazoline Hydrochloride per 0.2 ml spray)

Kovanaze TM Nasal Spray (6 mg Tetracaine Hydrochloride and 0.1 mg Oxymetazoline Hydrochloride per 0.2 ml spray) SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF SUBSTANCE Name: Product Code: NDC # 69803 100 10 (6 mg tetracaine and 0.1 mg oxymetazoline ) Recommended use: Restrictions on use: Manufacturer: Emergency

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 6 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Material Safety Data Sheet

Material Safety Data Sheet Material Safety Data Sheet NFPA HMIS Personal Protective Equipment 2 Health Hazard Fire Hazard 2 See Section 15. Section 1. Chemical Product and Company Identification Common Name/ Trade Name Manufacturer

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Chapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved.

Chapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved. Chapter 13 Preventing Infection Copyright 2019 by Elsevier, Inc. All rights reserved. Lesson 13.1 Define the key terms and key abbreviations in this chapter. Identify what microbes need to live and grow.

More information

Intrathecal. By the end of this chapter, you will be able to: Introduction. Chapter 20

Intrathecal. By the end of this chapter, you will be able to: Introduction. Chapter 20 Chapter 20 Intrathecal Preparations By the end of this chapter, you will be able to: l Describe the specific risks with intrathecal cytotoxic products l List five checks that need to be carried out on

More information

S A F E T Y D A T A S H E E T IntelliBond Vital 3

S A F E T Y D A T A S H E E T IntelliBond Vital 3 1. Identification of Substance and Supplier Product Name. Alternative Names Recommended Use of Chemical Use Restrictions Manufacturer s Information Emergency Phone Number GHS Classification of Substance

More information

AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT

AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT AMBULANCE DECONTAMINATION GUIDELINES SUSPECTED INFLUENZA PATIENT Reprinted with the Permission of John Hill, President Iowa EMS Association Following are general guidelines for cleaning or maintaining

More information

MEDICAL WASTE MANAGEMENT PLAN

MEDICAL WASTE MANAGEMENT PLAN Ventura County Environmental Health Division 800 S. Victoria Ave., Ventura CA 93009-1730 TELEPHONE: 805/477-7110 FAX: 805/477-1595 Internet Web Site Address: www.vcrma.org/medical-waste-program MEDICAL

More information

TOPIC 4 HANDLING HEALTH PROTECTION & SAFETY PRACTICES FOR MEDICAL STAFF & WASTE HANDLERS TRAINING & PUBLIC EDUCATION

TOPIC 4 HANDLING HEALTH PROTECTION & SAFETY PRACTICES FOR MEDICAL STAFF & WASTE HANDLERS TRAINING & PUBLIC EDUCATION TOPIC 4 HANDLING HEALTH PROTECTION & SAFETY PRACTICES FOR MEDICAL STAFF & WASTE HANDLERS TRAINING & PUBLIC EDUCATION Who Is AT RISK? Basic Questions Key Points General Principles Waste Handling Minimum

More information

Southern Trust Home IV Service. Guidelines for the administration of IV antibiotics

Southern Trust Home IV Service. Guidelines for the administration of IV antibiotics Southern Trust Home IV Service Guidelines for the administration of IV antibiotics Title: Author: CLINICAL GUIDELINES ID TAG Antibiotic guidelines - Southern Trust Home IV service guidelines for the administration

More information

EVER Pharma D-mine Pen Pen injector for Apomorphine 10 mg/ml

EVER Pharma D-mine Pen Pen injector for Apomorphine 10 mg/ml EVER Pharma D-mine Pen Pen injector for Apomorphine 10 mg/ml Instructions for Use with Dacepton 3 ml Cartridges Apomorphine hydrochloride hemihydrate solution for injection Subcutaneous Use TABLE OF CONTENTS

More information

Material Safety Data Sheet

Material Safety Data Sheet Material Safety Data Sheet Date: March 26, 2013 Product: Product Information: Product Code:: Iodine Spray 10L-ISPRA D.I.N. 0049600 Manufacturer/Supplier: Dominion Veterinary labs LTD. 1199 Sanford St Winnipeg,

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 7 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Personal protective equipment (PPE) requirements for personnel working with non-human primates at UT-Austin Version 3 09/07/18

Personal protective equipment (PPE) requirements for personnel working with non-human primates at UT-Austin Version 3 09/07/18 This ARC guideline has been written to clearly communicate current standards for the facility users. Questions should be directed to Nachi Shukla (512/232-2043) or Dr. Glen Otto (512/471-2392). Personal

More information